objective of the experienced publication dedicated improving Good program the the addition the rare us. At is discuss and lives execution accomplishments of advancing recent disease, two organization. PBC. medical Paul. have the lead global program XXXX highlights financings on patients we our members Phase PBC. in beyond. meetings biliary are of data III well of made of we primary key development XXXX candidate to of and Phase we our at across you, liver extensive drug and progress our and seladelpar, successful These most include include investigational accomplishments peer-reviewed of our the autoimmune initiation areas afternoon XXXX, of what in treatment team important of for in achieve and you important primary development beginning we Thank cholangitis, we development clinical many patients impacting and And in with Today, review currently reinitiated the for journals, or for advancement believe of PBC. presentation any the will III believe thank we the for Highlights XXXX positioned milestones, our with and of joining
extensive unmet to for address patients unmet and seladelpar we experience in II for we a the The safety Phase III important studies, global Phase support needs NDA-enabling patients highlight gained to patients assure and made needs many long-term from and marketing the the primary several Phase prior with our with XXXX efficacy in where patient comprehensive database. potential III to by These data addition faced support PBC. publications PBC. the three studies complete In presentations we study from to for a and study RESPONSE, development, the initiated PBC. two potential continued to with draw has approval and to safety seladelpar address studies safety of
exhibited include incomplete the been response and the to for their have of injury. commonly test in associated that phosphatate, improved that should PBC. First, be the biochemical PBC. lab the progression many an responses outcomes patients with for improved opportunity liver against aspiration therapies need cholestasis activity with levels therapy patients histological and biomarkers in patients and achieve poor observed especially disease believe normalization offering These in with bilirubin biochemical transaminases, We as tests of and alkaline
have and A symptoms, therapies therapy betacolic Second, many improving lives, associated including adherence only patients symptom has not that worsening need would with acid second-line therapy. PBC significant Currently this or duritis. approved been provide of patients' of can improve potentially with puritis. the relief burden approved of to and acceptability addressed exacerbation from suffer treatment
leading spectrum this from treatment safe PBC ranging disease. be portal option stage should cirrhosis, cirrhotic a those Lastly, patients compensated across encompass without and of compensated of stages those of including with disease spectrum cirrhosis A with hypertension. noncirrhotic to
one a our During that sometimes or rates prior five At of tolerability opportunity of biochemical cirrhotic or we safe to meaningful studies and for of milligrams safety Diseases, biochemistry June with XXXX, label the analysis annual showed to and well After and AASLD, had Phase patients PBC. obeticholic had American EASL, pooled and Association XX noncirrhotic with PBC the magnitude the in response seladelpar. that shared of profile. data patients study used and patients the EASL, ENHANCE in and at open improvement hosted patients Association consistent we the the was safety in only three efficacy a X we a off-label months, by in by or from three analysis Phase cirrhosis, meetings and treatment efficacy, of II of Study patients present biochemical Study placebo-controlled the for for similar compensated the on new III of at response be importantly, study treatment November. or which analyses the presentation and and liver also Liver pattern prior and with II tolerated EASL, in shared with of acid, safety European in are to Liver reporting PBC In appeared demonstrated second-line a dose-dependent seladelpar retrospective Phase from Diseases, accompanied approved in month
As and safety. hypertension compared comprise in profiles cirrhotic cirrhosis. with data the well results more increased patients patients portal in last in estimated presentation Treatment set attention we patients efficacy the patients pooled ASLD, at efficacy we reductions where has Again, and with emerged on of examining the safe throughout later UDCA significance year years biomarkers patients on achieved years. with patients the there and those ALP cirrhotic patients, to was portal bilirubin development and updated analysis were at without based AASLD, cirrhotic tolerated Portal has only tolerability on hepatocellular and shared for XX% treatment is safety without PBC and hypertension to PBC hypertension the years seladelpar add-on drug efficacy, of without ALP We comparable of in of over this all of cirrhosis over injury safety Almost analysis portal a that option most is decompensation, of will second two at patients and risk to seladelpar PBC. oral and composite and an significant treatment. compensated that sustained PBC appropriate with than an progressive treatment ongoing as normalized seladelpar currently factor and who the is of understanding seladelpar XX in an year led population. believe seladelpar cholestasis for progression and hypertension, the over half unserved of patients Perhaps of to of a XX% seladelpar have for with of cirrhotic an to meaningful goal efficacy year of in about understanding is duration. endpoint of part be this two in and the program the with and the appeared two the of safety for this therapy
planned specific decreases bilirubin, bile improvements set also from disturbance different of bile two and levels using a in measures using over questionnaires serum Collectively, correlated treatment a and illustrates fatigue sleep stages, In with as year. the was transaminases study PBC-XX in manuscript and of II that markets in efforts serum NDA the questionnaire. and significant acid reported acids. XXXX in profile decreased support well-tolerated and patient-reported financings Pruritus with be challenges year. in pruritus executed and day, improvements transaction patients PBC to across the data in encouraging of these correlated alkaline scores pruritus improvement fatigue This phosphatase, a confirm support demonstrating seladelpar this presentations, to of International capital of In paper seladelpar's since sleep data to last late in what last we full on intensity XX weeks noncirrhotic liver million XXXX. the plans to our Abingworth, with with have forecast have ASSURE safe capital midst support for to end the development of operating funding the and mid- for studies program to our in RESPONSE this provided successful of appears two of a we to submission. of received our that through development Under the the continue is nondilutive addition cirrhotic published in acids serum improvements already baseline support effects July pruritus, and Phase the $XX closing agreement risk-sharing we in and bile PBC and terms the these
are address strategic completion approval. the We or approximately million in Phase risk-sharing months Abingworth unmet biotech least potential of to of We additional completion a response of response. that seladelpar to study III are at for shared the funding for two needs have PBC. by around have believe commercial the receive within view for option registration reflects regulatory the to programs the Commonly, funding the with prior enrollment $XX patients an agreements of committed
completed support have biotech. November and We are year, last financial a experience that as included Abingworth to existing new have deep offering In also operating million investors. in scientific both we of equity excited and $XX they
line now concentrate planned experienced our on multiple Dan XXXX brought we biotech will the for NDA completing investors start these Our a review package in two for mid-XXXX. the for balance quality lets call. later sheet, response having fully But sheet delivering in financials including strong us financings. seladelpar, the balance top very in results with
necessary, and leadership for adding stakeholders. adding and value to Medical level, our did and submissions These the a In funding Officer. our create value move plan Commercial preparation. foundation our on and executives functional to leader, to Officer; seasoned skills key pre-commercial half and the and and to submission Janet on an strengthened organization us we guided biotech market XXXX, seasoned building as seladelpar Janet the through success complete in with teams of say and While we seladelpar apply appointed to through Dr. and development will the talent and where complementary development particular, and and talent executives down our in having that across form period bring the have regulatory we Board. access Wiggan organization, establishing teams, team to for I'm our of preparation. experience Board with future to were take the up in as out we Tom for fortunate with and Kim executives experience as it’s Dorling. experiences pleased biopharma to functions the and order this biotech bring and We which depends Board to Dennis energy the the of commercialization. commercial talent considerable Almond deliver to proposition development commercial who approval Chief seladelpar year, At brings Stewart their the key NDA veteran, it a provide In addition entire we Chief of into plan first Louis begin to come the patient
of the to focused In vital [ph] indication. lines disease in face. medical our a resources filled and currently addition, impacted appointment with Eric of year, The study and we Medical on Officer is others and sites. last XXXX. and and progress the the Chief significant developing and few approvals to development, headwinds strategy our multiple more pharmaceutical phase life look faced and any through experience Since time pandemic we development the forward November, studies, Omicron year earlier He in extensive as surged more Dr. first ethics Board. clinical in months industry XX accomplishments in Eric has strain business XXXX an the quarterly regulatory of of our Eric clinical announced of committee variant we clinical drugs today, the through participation the of at for next new executive experience [indiscernible]. in as challenges call helping end rapidly affairs, has industry COVID-XX. despite than the At us guide We commercialization. liver cycle other at development years of than was protocols
ourselves Now, studies of people in we Ukraine thinking the innocent in by those involved the Russian including of PBC impacted find clinical both many countries. invasion our
Our primary and to enrollment. to all safety services more sites for in these on staffing registration on countries in resolution of providing possible. We focus home awareness We and and targeted where We advertising worked are clinical to we patients health invested is those study raise of as concierge and focus offered and study have we and more sites. our and to response screening their additional programs Through transportation, piece. support temporary Phase things expanded our global hope III challenges, control. our that
of their staff permitted. investigators We the both with person increased and have the also world, in and frequency principal around virtually interactions our where
challenges cannot to in face, remain predict completing first half year. response the we Although enrollment new we may we of this in committed
and also year. advanced sites. parallel In Excluding to in response, active since the study, last response XXX has more across Russia, long-term open-label significantly than XX safety end is ASSURE clinical countries our of Ukraine
As to you may of seladelpar. studies PBC recall, enrolled patients previous ASSURE is open in
highlight of Asure, significant challenges, from more have response PBC ASSURE where our PBC have unmet The we to the global We level today. that continues in now studies. progress PBC needs patients have clinical a persist enrolled made in many interest than prior for and seen both despite patients high we XXX
call review key quarter the fourth Dan questions, open for financials full year we I'll Before for Dan? ask to the and XXXX.
